A central role of EGFR transactivation in chronic kidney diseases

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 1, 2007, Pages 47-53

  Terzi, Fabiola ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; METALLOPROTEINASE;

CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; HUMAN; KIDNEY INJURY; NONHUMAN; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION;

EID: 47249095411     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2007.06.007     Document Type: Review

References (53)

1. Hostetter T.H. Progression of renal disease and renal hypertrophy. Annu. Rev. Physiol. 57 (1995) 263-278
2. Harris R.C., et al. EGF receptor ligands. Exp. Cell Res. 284 (2003) 2-13
3. Ohtsu H., et al. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am. J. Physiol. Cell Physiol. 291 (2006) C1-C10
4. Jorissen R.N., et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284 (2003) 31-53
5. Prenzel N., et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402 (1999) 884-888
6. Normanno N., et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366 (2006) 2-16
7. Nouwen E.J., and De Broe M.E. EGF and TGF-alpha in the human kidney: identification of octopal cells in the collecting duct. Kidney Int. 45 (1994) 1510-1521
8. Breyer M.D., et al. Segmental distribution of epidermal growth factor binding sites in rabbit nephron. Am. J. Physiol. 259 (1990) F553-F558
9. Norman J., et al. EGF-induced mitogenesis in proximal tubular cells: potentiation by angiotensin II. Am. J. Physiol. 253 2 Pt 2 (1987) F299-F309
10. Okada H., et al. Early role of Fsp1 in epithelial-mesenchymal transformation. Am. J. Physiol. 273 4 Pt 2 (1997) F563-F574
11. Creely J.J., et al. Effects of epidermal growth factor on collagen synthesis by an epithelioid cell line derived from normal rat kidney. Am. J. Pathol. 136 (1990) 1247-1257
12. Sakurai H., et al. EGF receptor ligands are a large fraction of in vitro branching morphogens secreted by embryonic kidney. Am. J. Physiol. 273 3 Pt 2 (1997) F463-F472
13. Stocklin E., et al. An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. J. Cell Biol. 122 (1993) 199-208
14. Schaffner D.L., et al. Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am. J. Pathol. 142 (1993) 1051-1060
15. Lowden D.A., et al. Renal cysts in transgenic mice expressing transforming growth factor-alpha [see comments]. J. Lab. Clin. Med. 124 (1994) 386-394
16. Terzi F., et al. Targeted expression of a dominant negative Epidermal Growth Factor Receptor in the kidney reduces tubulo-interstitial lesions after renal injury. J. Clin. Invest. 106 (2000) 225-234
17. Richards W.G., et al. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J. Clin. Invest. 101 (1998) 935-939
18. Sweeney W.E., et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 57 (2000) 33-40
19. Francois H., et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB. J. 18 (2004) 926-928
20. Terzi F., et al. Early molecular mechanisms in the progression of renal failure: role of growth factors and protooncogenes. Kidney Int. Suppl. 53 (1998) S68-S73
21. Ardaillou R. Angiotensin II receptors. J. Am. Soc. Nephrol. 10 Suppl. 11 (1999) S30-S39
22. de Gasparo M., et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52 (2000) 415-472
23. Eguchi S., and Inagami T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul. Pept. 91 (2000) 13-20
24. Lafayette R.A., et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 90 (1992) 766-771
25. Pei Y., et al. Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J. Clin. Invest. 100 (1997) 814-820
26. Brewster U.C., and Perazella M.A. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 116 (2004) 263-272
27. Wolf G., and Neilson E.G. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am. J. Physiol. 259 5 Pt 2 (1990) F768-F777
28. Daub H., et al. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379 (1996) 557-560
29. 2+/calmodulin-dependent transactivation of epidermal growth factor receptor. Circ. Res. 82 (1998) 1338-1348
30. Eguchi S., et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J. Biol. Chem. 273 (1998) 8890-8896
31. Uchiyama-Tanaka Y., et al. Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int. 60 (2001) 2153-2163
32. Lautrette A., et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat. Med. 11 (2005) 867-874
33. Asakura M., et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 8 (2002) 35-40
34. Chen J., et al. Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J. Am. Soc. Nephrol. 17 (2006) 1615-1623
35. Hua H., et al. Endothelin-1 activates mesangial cell ERK1/2 via EGF-receptor transactivation and caveolin-1 interaction. Am. J. Physiol. Renal Physiol. 284 (2003) F303-F312
36. Chansel D., et al. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB. J. 20 (2006) 1936-1938
37. Neuhofer W., and Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur. J. Clin. Invest. 36 Suppl. 3 (2006) 78-88
38. Gooz M., et al. 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J. Biol. Chem. 281 (2006) 21004-21012
39. Ghosh P.M., et al. Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. Am. J. Physiol. Renal Physiol. 280 (2001) F972-F979
40. Fiebeler A., et al. Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr. Opin. Nephrol. Hypertens 16 (2007) 134-142
41. Zwick E., et al. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol. Sci. 20 (1999) 408-412
42. Konishi A., and Berk B.C. Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J. Biol. Chem. 278 (2003) 35049-35056
43. Saad S., et al. High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. Kidney Int. 68 (2005) 985-997
44. Cai W., et al. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13801-13806
45. Wassef L., et al. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int. 66 (2004) 1805-1814
46. Remuzzi G., et al. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116 (2006) 288-296
47. Reich H., et al. Albumin activates ERK via EGF receptor in human renal epithelial cells. J. Am. Soc. Nephrol. 16 (2005) 1266-1278
48. Ushio-Fukai M., et al. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 489-495
49. Tian W., and Cohen D.M. Signaling and gene regulation by urea in cells of the mammalian kidney medulla. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 130 (2001) 429-436
50. Zhao H., et al. Urea signalling to immediate-early gene transcription in renal medullary cells requires transactivation of the epidermal growth factor receptor. Biochem. J. 370 Pt 2 (2003) 479-487
51. Lezama R., et al. Epidermal growth factor receptor is a common element in the signaling pathways activated by cell volume changes in isosmotic, hyposmotic or hyperosmotic conditions. Neurochem. Res. 30 (2005) 1589-1597
52. Mackenzie H.S., et al. Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future. J. Am. Soc. Nephrol. 10 Suppl. 12 (1999) S283-S286
53. Laverman G.D., et al. Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?. J. Renin. Angiotensin Aldosterone Syst. 3 (2002) 205-213